BioCentury
ARTICLE | Preclinical News

On-target mutations latest worry for CRISPR stocks

July 16, 2018 4:04 PM UTC

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology. The Nature Biotechnology paper, which suggested CRISPR-Cas9 can produce large genomic deletions, sent CRISPR stocks tumbling Monday, shaving over $530 million in market cap from the companies’ collective value.

CRISPR Therapeutics AG (NASDAQ:CRSP) fell $5.65 to $60.06, Editas Medicine Inc. (NASDAQ:EDIT) slid $2.70 to $35.20 and Intellia Therapeutics Inc. (NASDAQ:NTLA) dropped $3.24 (10%) to $29.36. ...

BCIQ Company Profiles

Wellcome Sanger Institute